| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 204.00 mm | 204.00 mm | 204.00 mm | 204.00 mm | 204.00 mm | 204.00 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 35.00 mm | 26.50 mm | (no burn) | 13.17 mm |
| Cash used (since last report) | n/a | n/a | 140.77 mm | 106.58 mm | n/a | 52.96 mm |
| Cash remaining | n/a | n/a | 63.23 mm | 97.42 mm | n/a | 151.04 mm |
| Runway (months of cash) | n/a | n/a | 1.8 | 3.7 | n/a | 11.5 |
| 13F holders | Current |
|---|---|
| Total holders | 191 |
| Opened positions | 21 |
| Closed positions | 29 |
| Increased positions | 68 |
| Reduced positions | 69 |
| 13F shares | Current |
|---|---|
| Total value | 788.22 bn |
| Total shares | 93.25 mm |
| Total puts | 141.20 k |
| Total calls | 236.40 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| GILD Gilead Sciences | 31.53 mm | $603.85 mm |
| BlackRock | 9.73 mm | $148.81 bn |
| Vanguard | 5.47 mm | $83.62 bn |
| FMR | 4.47 mm | $68.31 bn |
| Woodline Partners | 3.48 mm | $53.19 bn |
| STT State Street | 3.01 mm | $46.04 bn |
| GV 2016 | 2.56 mm | $0.00 |
| Point72 Asset Management | 2.44 mm | $37.26 bn |
| Biotechnology Value Fund L P | 2.30 mm | $0.00 |
| Foresite Capital Fund III | 2.03 mm | $21.85 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Jan 25 | Goeltz II Robert C. | Common Stock | Grant | Acquire A | No | No | 0 | 37,000 | 0.00 | 97,138 |
| 23 Jan 25 | Goeltz II Robert C. | Stock Option Common Stock | Grant | Acquire A | No | No | 13.33 | 150,000 | 2.00 mm | 150,000 |
| 23 Jan 25 | Alexander Azoy | Common Stock | Grant | Acquire A | No | No | 0 | 17,100 | 0.00 | 30,194 |
| 23 Jan 25 | Alexander Azoy | Stock Option Common Stock | Grant | Acquire A | No | No | 13.33 | 11,400 | 151.96 k | 11,400 |
| 23 Jan 25 | Lacey David L. | Stock Option Common Stock | Grant | Acquire A | No | No | 13.33 | 5,000 | 66.65 k | 5,000 |
| 23 Jan 25 | Carolyn C. Tang | Common Stock | Grant | Acquire A | No | No | 0 | 37,000 | 0.00 | 137,623 |
| 23 Jan 25 | Carolyn C. Tang | Stock Option Common Stock | Grant | Acquire A | No | No | 13.33 | 150,000 | 2.00 mm | 150,000 |
| 23 Jan 25 | Rosen Terry J | Common Stock | Grant | Acquire A | No | No | 0 | 165,000 | 0.00 | 2,534,360 |
| 23 Jan 25 | Rosen Terry J | Stock Option Common Stock | Grant | Acquire A | No | No | 13.33 | 650,000 | 8.66 mm | 650,000 |
